Analyst firms · Barclays · LGND

Barclays LGND price target and rating history

Ligand Pharmaceuticals Incorporated (LGND) · Health Care

Barclays rates Ligand Pharmaceuticals Incorporated (LGND) Overweight with a $345 price target, as of its latest action on Sep 25, 2026. It has published 3 rating actions on LGND since September 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a LGND price target in the last 12 months, the median target is $345. Barclays's target matches it.

Current rating
Overweight
Price target
$345
Median target, all firms
$345
Actions on LGND
3

Barclays price target on LGND

$345$255$16520222023202420252026
Barclays price target on LGND, each point a stated target, September 2021 to September 2026.

Every Barclays rating on LGND

How other firms rate LGND

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$345Sep 25, 2026
Leerink PartnersOutperformAug 14, 2026
CitigroupBuy$387Jul 21, 2026
BofA SecuritiesBuy$244Mar 11, 2026

Questions about Barclays and LGND

What is Barclays's price target for LGND?
Barclays's latest stated price target for Ligand Pharmaceuticals Incorporated (LGND) is $345, from its action on Sep 25, 2026.
What is Barclays's rating on LGND?
Barclays rates LGND Overweight, a bullish rating, as of Sep 25, 2026.
When did Barclays last change its view on LGND?
On Sep 25, 2026, Barclays starts coverage at Overweight, price target $345.
How does Barclays's LGND target compare with other analysts?
Across 3 firms with a LGND price target in the last 12 months, the median target is $345. Barclays's target matches it.

All Barclays ratingsLGND news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.